{"id":1244,"date":"2023-10-11T08:59:01","date_gmt":"2023-10-11T08:59:01","guid":{"rendered":"https:\/\/onltherapeutics.com\/test\/?page_id=1244"},"modified":"2026-04-15T13:55:08","modified_gmt":"2026-04-15T13:55:08","slug":"homepage","status":"publish","type":"page","link":"https:\/\/onltherapeutics.com\/test\/","title":{"rendered":"ONL Therapeutics"},"content":{"rendered":"\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-cover alignfull is-light onl-intro-banner\" style=\"border-radius:66px;padding-right:var(--wp--preset--spacing--40);padding-left:var(--wp--preset--spacing--40);min-height:561px;aspect-ratio:unset;\"><video class=\"wp-block-cover__video-background intrinsic-ignore\" autoplay muted loop playsinline src=\"https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2025\/12\/ONL_Hero_Video.mp4\" poster=\"https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2025\/10\/ONL_Home-mov-image.jpg\" data-object-fit=\"cover\"><\/video><span aria-hidden=\"true\" class=\"wp-block-cover__background has-contrast-background-color has-background-dim-10 has-background-dim\"><\/span><div class=\"wp-block-cover__inner-container has-global-padding is-layout-constrained wp-container-core-cover-is-layout-97829e9f wp-block-cover-is-layout-constrained\">\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h6 class=\"wp-block-heading alignwide has-base-color has-text-color has-link-color wp-elements-2c9952fd16698bd039b384fd6ce4006a\" style=\"padding-top:0;padding-right:0;padding-bottom:0;padding-left:0;font-size:clamp(1.6rem, 1.6rem + ((1vw - 0.2rem) * 2.588), 2.7rem);text-transform:none\"><strong>ONL Therapeutics<\/strong> develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions<\/h6>\n\n\n\n<div class=\"wp-block-buttons alignwide is-layout-flex wp-container-core-buttons-is-layout-9bedd9bf wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-base-color has-custom-blue-background-color has-text-color has-background wp-element-button\" href=\"https:\/\/onltherapeutics.com\/test\/about-2\/\" style=\"border-radius:14px\">Learn More <\/a><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:78px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns alignwide home-section-wrap is-layout-flex wp-container-core-columns-is-layout-21f94789 wp-block-columns-is-layout-flex\" style=\"padding-right:0;padding-left:0\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-954ec4bb wp-block-columns-is-layout-flex\" style=\"padding-right:var(--wp--preset--spacing--40);padding-left:var(--wp--preset--spacing--40)\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:50%\">\n<h3 class=\"wp-block-heading has-text-color\" style=\"color:#5d657d;margin-left:0;padding-right:10px;padding-left:0;font-style:normal;font-weight:500;line-height:1.3;text-transform:none\">ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future<\/h3>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-right:0;padding-left:20px\">\n<p style=\"padding-top:0;padding-bottom:0;font-size:clamp(18.959px, 1.185rem + ((1vw - 3.2px) * 1.624), 30px);\"><a href=\"https:\/\/onltherapeutics.com\/test\/clinical-trials\/\">Clinical Trials<\/a><\/p>\n\n\n\n<p class=\"has-custom-dark-blue-color has-text-color\" style=\"margin-top:0px;margin-bottom:0px;line-height:1.5\">ONL\u2019s lead therapeutic candidate, xelafaslatide (formerly ONL1204), is a first-in-class small peptide that is being studied in multiple diseases.<\/p>\n\n\n\n<div class=\"wp-block-stackable-button-group stk-block-button-group stk-block stk-c818368\" data-block-id=\"c818368\"><div class=\"stk-row stk-inner-blocks stk-block-content stk-button-group\">\n<div class=\"wp-block-stackable-button stk-block-button stk-block stk-89c3cb4\" data-block-id=\"89c3cb4\"><style>.stk-89c3cb4 {border-top-left-radius:7px !important;border-top-right-radius:7px !important;border-bottom-right-radius:7px !important;border-bottom-left-radius:7px !important;overflow:hidden !important;}.stk-89c3cb4 .stk-button{min-height:14px !important;padding-top:0px !important;padding-right:0px !important;padding-bottom:0px !important;padding-left:0px !important;background:#ffffff !important;}.stk-89c3cb4 .stk-button .stk--inner-svg svg:last-child{height:12px !important;width:12px !important;margin-inline-start:1px !important;}.stk-89c3cb4 .stk-button .stk--inner-svg svg:last-child, .stk-89c3cb4 .stk-button .stk--inner-svg svg:last-child :is(g, path, rect, polygon, ellipse){fill:#00aeef !important;}.stk-89c3cb4 .stk-button__inner-text{font-size:14px !important;color:#00aeef !important;}@media screen and (max-width: 1023px){.stk-89c3cb4 .stk-button__inner-text{font-size:14px !important;}}<\/style><a class=\"stk-link stk-button stk--hover-effect-darken\" href=\"\"><span class=\"has-text-color stk-button__inner-text\">Explore Our Studies<\/span><span class=\"stk--svg-wrapper\"><div class=\"stk--inner-svg\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 320 512\" aria-hidden=\"true\" width=\"32\" height=\"32\"><path d=\"M310.6 233.4c12.5 12.5 12.5 32.8 0 45.3l-192 192c-12.5 12.5-32.8 12.5-45.3 0s-12.5-32.8 0-45.3L242.7 256 73.4 86.6c-12.5-12.5-12.5-32.8 0-45.3s32.8-12.5 45.3 0l192 192z\"\/><\/svg><\/div><\/span><\/a><\/div>\n<\/div><\/div>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-top:0;padding-right:0;padding-bottom:0;padding-left:20px\">\n<p style=\"padding-top:0;padding-bottom:0;font-size:clamp(18.959px, 1.185rem + ((1vw - 3.2px) * 1.624), 30px);\"><a href=\"https:\/\/onltherapeutics.com\/test\/science\/\">Science<\/a><\/p>\n\n\n\n<p class=\"has-custom-dark-blue-color has-text-color\" style=\"margin-top:0px;margin-right:0;margin-bottom:0px;line-height:1.5\">Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.<\/p>\n\n\n\n<div class=\"wp-block-stackable-button-group stk-block-button-group stk-block stk-bffdae8\" data-block-id=\"bffdae8\"><div class=\"stk-row stk-inner-blocks stk-block-content stk-button-group\">\n<div class=\"wp-block-stackable-button stk-block-button stk-block stk-9f4c6e7\" data-block-id=\"9f4c6e7\"><style>.stk-9f4c6e7 {border-top-left-radius:7px !important;border-top-right-radius:7px !important;border-bottom-right-radius:7px !important;border-bottom-left-radius:7px !important;overflow:hidden !important;}.stk-9f4c6e7 .stk-button{min-height:14px !important;padding-top:0px !important;padding-right:0px !important;padding-bottom:0px !important;padding-left:0px !important;background:#ffffff !important;}.stk-9f4c6e7 .stk-button .stk--inner-svg svg:last-child{height:12px !important;width:12px !important;margin-inline-start:1px !important;}.stk-9f4c6e7 .stk-button .stk--inner-svg svg:last-child, .stk-9f4c6e7 .stk-button .stk--inner-svg svg:last-child :is(g, path, rect, polygon, ellipse){fill:#00aeef !important;}.stk-9f4c6e7 .stk-button__inner-text{font-size:14px !important;color:#00aeef !important;}@media screen and (max-width: 1023px){.stk-9f4c6e7 .stk-button__inner-text{font-size:14px !important;}}<\/style><a class=\"stk-link stk-button stk--hover-effect-darken\" href=\"\"><span class=\"has-text-color stk-button__inner-text\">Explore the Fas Pathway<\/span><span class=\"stk--svg-wrapper\"><div class=\"stk--inner-svg\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 320 512\" aria-hidden=\"true\" width=\"32\" height=\"32\"><path d=\"M310.6 233.4c12.5 12.5 12.5 32.8 0 45.3l-192 192c-12.5 12.5-32.8 12.5-45.3 0s-12.5-32.8 0-45.3L242.7 256 73.4 86.6c-12.5-12.5-12.5-32.8 0-45.3s32.8-12.5 45.3 0l192 192z\"\/><\/svg><\/div><\/span><\/a><\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:48px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns alignwide home-section-wrap home-section-wrap2 has-custom-blue-background-color has-background is-layout-flex wp-container-core-columns-is-layout-3d258de0 wp-block-columns-is-layout-flex\" style=\"border-radius:40px;margin-top:0;margin-bottom:0;padding-top:30px;padding-bottom:30px\">\n<div class=\"wp-block-column is-vertically-aligned-top has-custom-blue-background-color has-background is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"has-base-color has-custom-blue-background-color has-text-color has-background\">By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top has-custom-blue-background-color has-background is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:40%\">\n<blockquote class=\"wp-block-quote is-style-plain has-base-color has-custom-blue-background-color has-text-color has-background is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-base-color has-text-color\" style=\"margin-bottom:0px;padding-bottom:12px;font-size:clamp(15.747px, 0.984rem + ((1vw - 3.2px) * 1.214), 24px);\"><em>&#8220;At ONL, we&#8217;re creating a whole new approach to solving vision problems affecting millions of people, whose options until now have been severely limited.&#8221;<\/em><\/p>\n<cite><strong>David Zacks, MD, PhD<\/strong><br>Co-Founder and<br>Chief Scientific Officer<br><\/cite><\/blockquote>\n<\/div>\n\n\n\n<div class=\"wp-block-column has-custom-blue-background-color has-background is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-top:12px;flex-basis:20%\">\n<figure class=\"wp-block-image size-full has-custom-border\"><img loading=\"lazy\" decoding=\"async\" width=\"328\" height=\"363\" src=\"https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2024\/01\/David_Zacks_home.png\" alt=\"David Zacks\" class=\"wp-image-1823\" style=\"border-radius:30px\" srcset=\"https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2024\/01\/David_Zacks_home.png 328w, https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2024\/01\/David_Zacks_home-271x300.png 271w\" sizes=\"auto, (max-width: 328px) 100vw, 328px\" \/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:70px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h1 class=\"wp-block-heading alignwide home-section-wrap home-section-wrap3 has-custom-green-color has-text-color\" style=\"margin-left:var(--wp--preset--spacing--30);padding-top:0;padding-right:0;padding-bottom:0;padding-left:0;font-size:clamp(1.743rem, 1.743rem + ((1vw - 0.2rem) * 2.958), 3rem);\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-green-color\"><a href=\"https:\/\/onltherapeutics.com\/test\/news\/\">News<\/a><\/mark><\/h1>\n\n\n\n<main class=\"wp-block-group alignwide home-section-wrap home-section-wrap4 has-base-background-color has-background is-layout-flow wp-block-group-is-layout-flow\" style=\"margin-top:0;margin-bottom:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--40);padding-left:var(--wp--preset--spacing--40)\">\n<div class=\"wp-block-query alignwide is-layout-flow wp-block-query-is-layout-flow\"><ul class=\"columns-3 wp-block-post-template is-layout-grid wp-container-core-post-template-is-layout-6d3fbd8f wp-block-post-template-is-layout-grid\"><li class=\"wp-block-post post-2801 post type-post status-publish format-standard hentry category-news category-onl-therapeutics-news\">\n\n<div class=\"wp-block-group has-base-background-color has-background is-layout-flow wp-container-core-group-is-layout-bd6b11fb wp-block-group-is-layout-flow\" style=\"border-radius:50px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n<hr class=\"wp-block-separator has-text-color has-custom-green-color has-alpha-channel-opacity has-custom-green-background-color has-background is-style-wide\"\/>\n\n\n<h4 style=\"font-size:clamp(15.747px, 0.984rem + ((1vw - 3.2px) * 1.214), 24px);\" class=\"has-link-color wp-elements-45a1961bde688208e961f019f18523d1 wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2026\/03\/16\/onl-therapeutics-announces-first-european-patient-randomized-in-its-global-phase-2-galaxy-trial-of-xelafaslatide-onl1204-in-patients-with-geographic-atrophy-ga-associated-with-dry-amd\/\" target=\"_self\" >ONL Therapeutics Announces First European Patient Randomized in its Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD<\/a><\/h4>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2026-03-16T07:49:00+00:00\">March 16, 2026<\/time><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-2641 post type-post status-publish format-standard hentry category-news category-onl-therapeutics-news\">\n\n<div class=\"wp-block-group has-base-background-color has-background is-layout-flow wp-container-core-group-is-layout-bd6b11fb wp-block-group-is-layout-flow\" style=\"border-radius:50px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n<hr class=\"wp-block-separator has-text-color has-custom-green-color has-alpha-channel-opacity has-custom-green-background-color has-background is-style-wide\"\/>\n\n\n<h4 style=\"font-size:clamp(15.747px, 0.984rem + ((1vw - 3.2px) * 1.214), 24px);\" class=\"has-link-color wp-elements-45a1961bde688208e961f019f18523d1 wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2025\/12\/09\/onl-therapeutics-announces-publication-of-data-from-phase-1b-study-of-xelafaslatide-an-investigational-therapy-for-geographic-atrophy-in-ophthalmology-science\/\" target=\"_self\" >ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science<\/a><\/h4>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2025-12-09T03:38:39+00:00\">December 9, 2025<\/time><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-2608 post type-post status-publish format-standard hentry category-news category-onl-therapeutics-news\">\n\n<div class=\"wp-block-group has-base-background-color has-background is-layout-flow wp-container-core-group-is-layout-bd6b11fb wp-block-group-is-layout-flow\" style=\"border-radius:50px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n<hr class=\"wp-block-separator has-text-color has-custom-green-color has-alpha-channel-opacity has-custom-green-background-color has-background is-style-wide\"\/>\n\n\n<h4 style=\"font-size:clamp(15.747px, 0.984rem + ((1vw - 3.2px) * 1.214), 24px);\" class=\"has-link-color wp-elements-45a1961bde688208e961f019f18523d1 wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2025\/11\/10\/onl-therapeutics-to-present-at-eyenovate-and-the-floretina-icoor-congress-2025\/\" target=\"_self\" >ONL Therapeutics to Present at EYENOVATE and the FLORetina\u2013ICOOR Congress 2025<\/a><\/h4>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2025-11-10T07:00:00+00:00\">November 10, 2025<\/time><\/div><\/div>\n\n<\/li><\/ul><\/div>\n<\/main>\n","protected":false},"excerpt":{"rendered":"<p>ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future Clinical Trials ONL\u2019s lead therapeutic candidate, xelafaslatide (formerly ONL1204), is a first-in-class small peptide that is being studied in multiple diseases. Explore Our Studies Science Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":72,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"blank","meta":{"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-1244","page","type-page","status-publish","has-post-thumbnail","hentry"],"featured_image_urls_v2":{"full":["https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2023\/08\/ONL_LOGO_SIZES_ONL_LOGO_LG_POS-1.png",1705,925,false],"thumbnail":["https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2023\/08\/ONL_LOGO_SIZES_ONL_LOGO_LG_POS-1-150x150.png",150,150,true],"medium":["https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2023\/08\/ONL_LOGO_SIZES_ONL_LOGO_LG_POS-1-300x163.png",300,163,true],"medium_large":["https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2023\/08\/ONL_LOGO_SIZES_ONL_LOGO_LG_POS-1-768x417.png",768,417,true],"large":["https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2023\/08\/ONL_LOGO_SIZES_ONL_LOGO_LG_POS-1-1024x556.png",1024,556,true],"1536x1536":["https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2023\/08\/ONL_LOGO_SIZES_ONL_LOGO_LG_POS-1-1536x833.png",1536,833,true],"2048x2048":["https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2023\/08\/ONL_LOGO_SIZES_ONL_LOGO_LG_POS-1.png",1705,925,false],"gform-image-choice-sm":["https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2023\/08\/ONL_LOGO_SIZES_ONL_LOGO_LG_POS-1.png",300,163,false],"gform-image-choice-md":["https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2023\/08\/ONL_LOGO_SIZES_ONL_LOGO_LG_POS-1.png",400,217,false],"gform-image-choice-lg":["https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2023\/08\/ONL_LOGO_SIZES_ONL_LOGO_LG_POS-1.png",600,326,false]},"post_excerpt_stackable_v2":"<p>ONL Therapeutics develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions Learn More ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future Clinical Trials ONL\u2019s lead therapeutic candidate, xelafaslatide (formerly ONL1204), is a first-in-class small peptide that is being studied in multiple diseases. Explore Our Studies Science Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases. Explore the Fas Pathway By advancing a breakthrough technology designed to prevent&hellip;<\/p>\n","category_list_v2":"","author_info_v2":{"name":"theo@myriadweb.com","url":"https:\/\/onltherapeutics.com\/test\/author\/theomyriadweb-com\/"},"comments_num_v2":"0 comments","_links":{"self":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/1244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/comments?post=1244"}],"version-history":[{"count":73,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/1244\/revisions"}],"predecessor-version":[{"id":2833,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/1244\/revisions\/2833"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/media\/72"}],"wp:attachment":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/media?parent=1244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}